Canada
· Delayed Price · Currency is CAD Biosenta Statistics
Total Valuation
Biosenta has a market cap or net worth of CAD 4.13 million. The enterprise value is 10.50 million.
| Market Cap | 4.13M |
| Enterprise Value | 10.50M |
Important Dates
The next estimated earnings date is Tuesday, January 27, 2026.
| Earnings Date | Jan 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biosenta has 34.46 million shares outstanding. The number of shares has increased by 7.64% in one year.
| Current Share Class | 34.46M |
| Shares Outstanding | 34.46M |
| Shares Change (YoY) | +7.64% |
| Shares Change (QoQ) | +2.52% |
| Owned by Insiders (%) | 25.60% |
| Owned by Institutions (%) | n/a |
| Float | 25.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -20.87 |
| PB Ratio | -0.43 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.07 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -23.73 |
Financial Position
The company has a current ratio of 0.02
| Current Ratio | 0.02 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -14.39 |
| Interest Coverage | -1.09 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -374.05% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 37.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | 0.02 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.11 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 49.84 |
| Average Volume (20 Days) | 9,818 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biosenta had revenue of CAD -198,147 and -2.58 million in losses. Loss per share was -0.08.
| Revenue | -198,147 |
| Gross Profit | -198,879 |
| Operating Income | -1.35M |
| Pretax Income | -2.58M |
| Net Income | -2.58M |
| EBITDA | -1.35M |
| EBIT | -1.35M |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 4,690 in cash and 6.37 million in debt, giving a net cash position of -6.36 million or -0.18 per share.
| Cash & Cash Equivalents | 4,690 |
| Total Debt | 6.37M |
| Net Cash | -6.36M |
| Net Cash Per Share | -0.18 |
| Equity (Book Value) | -9.51M |
| Book Value Per Share | -0.28 |
| Working Capital | -3.69M |
Cash Flow
In the last 12 months, operating cash flow was -416,464 and capital expenditures -25,861, giving a free cash flow of -442,325.
| Operating Cash Flow | -416,464 |
| Capital Expenditures | -25,861 |
| Free Cash Flow | -442,325 |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | 682.84% |
| Pretax Margin | 1,302.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biosenta does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.64% |
| Shareholder Yield | -7.64% |
| Earnings Yield | -62.43% |
| FCF Yield | -10.70% |
Stock Splits
The last stock split was on June 28, 2016. It was a reverse split with a ratio of 0.0666666666.
| Last Split Date | Jun 28, 2016 |
| Split Type | Reverse |
| Split Ratio | 0.0666666666 |
Scores
Biosenta has an Altman Z-Score of -361.31 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -361.31 |
| Piotroski F-Score | 2 |